Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Vinuesa, S. G.
Right arrow Articles by Valderrábano, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by de Vinuesa, S. G.
Right arrow Articles by Valderrábano, F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 78-81
© 2001 European Renal Association-European Dialysis and Transplant Association

Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs

Soledad García de Vinuesa, José Luño, Francisco Gómez-Campderá, Natalia Ridao, Mercedes Sánchez, Cecilia Dall'Anese and Fernando Valderrábano

Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Background. The severity of proteinuria is the main predictive factor in the progression of renal failure in chronic nephropathies. Therefore, action aimed at reducing proteinuria should be a priority in the treatment of these patients. Various antihypertensive drugs, in particular the angiotensin-converting enzyme inhibitors (ACEIs), have a greater antiproteinuric effect, although it is difficult to establish whether this is due only to their effect on arterial blood pressure (BP) or to other mechanisms associated with blockade of the renin–angiotensin system (RAS).

Methods. The evolution of proteinuria after two successive treatment periods was studied prospectively for 2 years in 22 patients with chronic glomerulonephritis. In period I, which lasted for 12 months, BP was strictly controlled (<125/75 mmHg) and the patients received random and double-blind treatment with a ß-blocker (ßB), atenolol; a non-dihydropyridine calcium channel blocker (CCB), verapamil; an ACEI, trandolapril; or a fixed combination of the latter two. In period II, all of the patients received treatment openly for an additional 12 months with a fixed combination of verapamil+trandolapril at half the dose of the preceding period, to obtain conventional control of BP at <140/90 mmHg.

Results. The mean level for basal SBP/DBP was 136±14/86±7 mmHg, which decreased in period I to 121±15/76±8 mmHg (P=0.01) and to 124±5/78 ±8 mmHg (P<0.05) at 6 and 12 months of treatment, respectively. There were no differences in the BP reached in the four therapy groups; however, proteinuria only decreased in the patients treated with trandolapril alone or in combination with verapamil. In period II, BP levels rose to 134±10/84±8 mmHg (P<0.05); this increase in BP was accompanied by an increase in proteinuria in those patients who had received the ACEI alone or in combination in the previous period, while in patients previously treated with a ßB or a CCB, proteinuria decreased, in spite of the increase in BP.

Conclusions. With equal BP control, treatment with the ACEI trandolapril alone, or in combination with a CCB, has a greater antiproteinuric effect than that obtained with other antihypertensive drugs, but this effect is attenuated if BP is not strictly controlled.

Keywords: angiotensin-converting enzyme inhibitors (ACEIs); blood pressure control; chronic glomerulonephritis; chronic non-diabetic nephropathies; proteinuria; renal disease

Correspondence and offprint requests to: S. García de Vinuesa, Department of Nephrology, Hospital General Universitario Gregorio Marañón, Dr Esquerdo, 46, 28007 Madrid, Spain.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.